EGFR fusions as novel therapeutic targets in lung cancer

Kartik Konduri, Jean Nicolas Gallant, Young Kwang Chae, Francis J. Giles, Barbara J. Gitlitz, Kyle Gowen, Eiki Ichihara, Taofeek K. Owonikoko, Vijay Peddareddigari, Suresh S. Ramalingam, Satyanarayan K. Reddy, Beth Eaby-Sandy, Tiziana Vavalà, Andrew Whiteley, Heidi Chen, Yingjun Yan, Jonathan H. Sheehan, Jens Meiler, Deborah Morosini, Jeffrey S. Ross & 4 others Philip J. Stephens, Vincent A. Miller, Siraj M. Ali, Christine M. Lovly

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising the N-terminal of EGFR linked to various fusion partners, most commonly RAD51, are recurrent in lung cancer. We describe five patients with metastatic lung cancer whose tumors harbored EGFR fusions, four of whom were treated with EGFR tyrosine kinase inhibitors (TKI) with documented antitumor responses. In vitro, EGFR-RAD51 fusions are oncogenic and can be therapeutically targeted with available EGFR TKIs and therapeutic antibodies. These results support the dependence of EGFR-rearranged tumors on EGFR-mediated signaling and suggest several therapeutic strategies for patients whose tumors harbor this novel alteration. SIGNIFICANCE: We report for the first time the identification and therapeutic targeting of EGFR C-terminal fusions in patients with lung cancer and document responses to the EGFR inhibitor erlotinib in 4 patients whose tumors harbored EGFR fusions. Findings from these studies will be immediately translatable to the clinic, as there are already several approved EGFR inhibitors.

Original languageEnglish
Pages (from-to)601-611
Number of pages11
JournalCancer Discovery
Volume6
Issue number6
DOIs
Publication statusPublished - Jun 1 2016
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Therapeutics
Neoplasms
erbB-1 Genes
Gene Fusion
Protein-Tyrosine Kinases
Antibodies

ASJC Scopus subject areas

  • Oncology

Cite this

Konduri, K., Gallant, J. N., Chae, Y. K., Giles, F. J., Gitlitz, B. J., Gowen, K., ... Lovly, C. M. (2016). EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discovery, 6(6), 601-611. https://doi.org/10.1158/2159-8290.CD-16-0075

EGFR fusions as novel therapeutic targets in lung cancer. / Konduri, Kartik; Gallant, Jean Nicolas; Chae, Young Kwang; Giles, Francis J.; Gitlitz, Barbara J.; Gowen, Kyle; Ichihara, Eiki; Owonikoko, Taofeek K.; Peddareddigari, Vijay; Ramalingam, Suresh S.; Reddy, Satyanarayan K.; Eaby-Sandy, Beth; Vavalà, Tiziana; Whiteley, Andrew; Chen, Heidi; Yan, Yingjun; Sheehan, Jonathan H.; Meiler, Jens; Morosini, Deborah; Ross, Jeffrey S.; Stephens, Philip J.; Miller, Vincent A.; Ali, Siraj M.; Lovly, Christine M.

In: Cancer Discovery, Vol. 6, No. 6, 01.06.2016, p. 601-611.

Research output: Contribution to journalArticle

Konduri, K, Gallant, JN, Chae, YK, Giles, FJ, Gitlitz, BJ, Gowen, K, Ichihara, E, Owonikoko, TK, Peddareddigari, V, Ramalingam, SS, Reddy, SK, Eaby-Sandy, B, Vavalà, T, Whiteley, A, Chen, H, Yan, Y, Sheehan, JH, Meiler, J, Morosini, D, Ross, JS, Stephens, PJ, Miller, VA, Ali, SM & Lovly, CM 2016, 'EGFR fusions as novel therapeutic targets in lung cancer', Cancer Discovery, vol. 6, no. 6, pp. 601-611. https://doi.org/10.1158/2159-8290.CD-16-0075
Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K et al. EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discovery. 2016 Jun 1;6(6):601-611. https://doi.org/10.1158/2159-8290.CD-16-0075
Konduri, Kartik ; Gallant, Jean Nicolas ; Chae, Young Kwang ; Giles, Francis J. ; Gitlitz, Barbara J. ; Gowen, Kyle ; Ichihara, Eiki ; Owonikoko, Taofeek K. ; Peddareddigari, Vijay ; Ramalingam, Suresh S. ; Reddy, Satyanarayan K. ; Eaby-Sandy, Beth ; Vavalà, Tiziana ; Whiteley, Andrew ; Chen, Heidi ; Yan, Yingjun ; Sheehan, Jonathan H. ; Meiler, Jens ; Morosini, Deborah ; Ross, Jeffrey S. ; Stephens, Philip J. ; Miller, Vincent A. ; Ali, Siraj M. ; Lovly, Christine M. / EGFR fusions as novel therapeutic targets in lung cancer. In: Cancer Discovery. 2016 ; Vol. 6, No. 6. pp. 601-611.
@article{48cd0d70f7a142168f0f1643c6eff34d,
title = "EGFR fusions as novel therapeutic targets in lung cancer",
abstract = "Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising the N-terminal of EGFR linked to various fusion partners, most commonly RAD51, are recurrent in lung cancer. We describe five patients with metastatic lung cancer whose tumors harbored EGFR fusions, four of whom were treated with EGFR tyrosine kinase inhibitors (TKI) with documented antitumor responses. In vitro, EGFR-RAD51 fusions are oncogenic and can be therapeutically targeted with available EGFR TKIs and therapeutic antibodies. These results support the dependence of EGFR-rearranged tumors on EGFR-mediated signaling and suggest several therapeutic strategies for patients whose tumors harbor this novel alteration. SIGNIFICANCE: We report for the first time the identification and therapeutic targeting of EGFR C-terminal fusions in patients with lung cancer and document responses to the EGFR inhibitor erlotinib in 4 patients whose tumors harbored EGFR fusions. Findings from these studies will be immediately translatable to the clinic, as there are already several approved EGFR inhibitors.",
author = "Kartik Konduri and Gallant, {Jean Nicolas} and Chae, {Young Kwang} and Giles, {Francis J.} and Gitlitz, {Barbara J.} and Kyle Gowen and Eiki Ichihara and Owonikoko, {Taofeek K.} and Vijay Peddareddigari and Ramalingam, {Suresh S.} and Reddy, {Satyanarayan K.} and Beth Eaby-Sandy and Tiziana Vaval{\`a} and Andrew Whiteley and Heidi Chen and Yingjun Yan and Sheehan, {Jonathan H.} and Jens Meiler and Deborah Morosini and Ross, {Jeffrey S.} and Stephens, {Philip J.} and Miller, {Vincent A.} and Ali, {Siraj M.} and Lovly, {Christine M.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1158/2159-8290.CD-16-0075",
language = "English",
volume = "6",
pages = "601--611",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - EGFR fusions as novel therapeutic targets in lung cancer

AU - Konduri, Kartik

AU - Gallant, Jean Nicolas

AU - Chae, Young Kwang

AU - Giles, Francis J.

AU - Gitlitz, Barbara J.

AU - Gowen, Kyle

AU - Ichihara, Eiki

AU - Owonikoko, Taofeek K.

AU - Peddareddigari, Vijay

AU - Ramalingam, Suresh S.

AU - Reddy, Satyanarayan K.

AU - Eaby-Sandy, Beth

AU - Vavalà, Tiziana

AU - Whiteley, Andrew

AU - Chen, Heidi

AU - Yan, Yingjun

AU - Sheehan, Jonathan H.

AU - Meiler, Jens

AU - Morosini, Deborah

AU - Ross, Jeffrey S.

AU - Stephens, Philip J.

AU - Miller, Vincent A.

AU - Ali, Siraj M.

AU - Lovly, Christine M.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising the N-terminal of EGFR linked to various fusion partners, most commonly RAD51, are recurrent in lung cancer. We describe five patients with metastatic lung cancer whose tumors harbored EGFR fusions, four of whom were treated with EGFR tyrosine kinase inhibitors (TKI) with documented antitumor responses. In vitro, EGFR-RAD51 fusions are oncogenic and can be therapeutically targeted with available EGFR TKIs and therapeutic antibodies. These results support the dependence of EGFR-rearranged tumors on EGFR-mediated signaling and suggest several therapeutic strategies for patients whose tumors harbor this novel alteration. SIGNIFICANCE: We report for the first time the identification and therapeutic targeting of EGFR C-terminal fusions in patients with lung cancer and document responses to the EGFR inhibitor erlotinib in 4 patients whose tumors harbored EGFR fusions. Findings from these studies will be immediately translatable to the clinic, as there are already several approved EGFR inhibitors.

AB - Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising the N-terminal of EGFR linked to various fusion partners, most commonly RAD51, are recurrent in lung cancer. We describe five patients with metastatic lung cancer whose tumors harbored EGFR fusions, four of whom were treated with EGFR tyrosine kinase inhibitors (TKI) with documented antitumor responses. In vitro, EGFR-RAD51 fusions are oncogenic and can be therapeutically targeted with available EGFR TKIs and therapeutic antibodies. These results support the dependence of EGFR-rearranged tumors on EGFR-mediated signaling and suggest several therapeutic strategies for patients whose tumors harbor this novel alteration. SIGNIFICANCE: We report for the first time the identification and therapeutic targeting of EGFR C-terminal fusions in patients with lung cancer and document responses to the EGFR inhibitor erlotinib in 4 patients whose tumors harbored EGFR fusions. Findings from these studies will be immediately translatable to the clinic, as there are already several approved EGFR inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85011990388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011990388&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-16-0075

DO - 10.1158/2159-8290.CD-16-0075

M3 - Article

VL - 6

SP - 601

EP - 611

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 6

ER -